2024-12 Current Treatment Strategies 2024
CE Information
15.0 CME credits (15.0 pharmacology)Completion Time
15 hoursAvailable Until
December 11, 2027Posted By
University Learning SystemsNavigate
Overview
Specialties
Adult, Family, and GerontologicalClinical Topics
Depression, Kidney Disease, Pain, and PharmacologySession 1: Pharmacotherapy of Chronic Kidney Disease
Session 2: Current Practice Update: Opioids, Cannabinoids and Gabapentenoids for Managing Pain
Session 3: Protecting the Vulnerable: Improving Safety of Antimicrobials in the Elderly , Mastering Migraine Management , Latest in Pharmacotherapy for Weight Loss
Learning Objectives
Session 1: Pharmacotherapy of Chronic Kidney Disease
1. Discuss the mechanisms of action, role and pros/cons of SGLT2-inhibitors and finerenone in the prevention of CKD progression.
2. Discuss the mechanisms of action, pharmacokinetic, and pharmacodynamic characteristics of loop and thiazide diuretic agents.
3. Describe the mechanisms of action and pros/cons of therapies for the management of hyperkalemia, anemia, and CKD-MBD.
4. Choose an appropriate management for edema, acute and chronic hyperkalemia, anemia, and CKD-MDB in a patient with CKD.
5. Discuss the mechanisms of action, role and pros/cons of current and emerging therapies for the treatment of IgA Nephropathy.
Session 2: Current Practice Update: Opioids, Cannabinoids and Gabapentenoids for Managing Pain
Discuss the burden of opioid misuse and abuse on the individual and society.
2. Describe the funda- mental concepts of pain management, including: a) addiction; b) tolerance; c) dependency; d) hyperalgesia; e) allodynia.
3. State key principles for assessing patients in pain, identifying risk factors and behaviors that are associated with opioid misuse, abuse, and addiction.
4. Describe the similarities and differences in the mechanism of action for opioids, cannabinoids and gabapentenoids.
5. Compare and contrast the benefits, risks and role of opioids, cannabinoids and gabapentenoids in managing pain.
6. Describe the best practice model for properly monitoring patients who are started on opioids, gabapentenoids and cannabinoids to minimize the risks of adverse reactions, over-dosage and inappropriate compliance.
7. Compare and contrast the following product formulations of gabapentenoids with respect to their benefits and risks in managing pain: a) gabapentin (Neurontin); b) Horizant; c) Gralise; and, d) Lyrica.
8. Compare and contrast the most common cannabinoids found in marijuana with regards to their benefits and risks in managing pain and other symptoms.
9. State the risks of combining opioids with: a) benzodiazepines; b) alcohol; c) gabapentenoids; and d) cannabinoids.
10. Describe how to counsel patients and caregivers regarding the safe use on naloxone for opioid overdose
Session 3: Protecting the Vulnerable: Improving Safety of Antimicrobials in the Elderly , Mastering Migraine Management , Latest in Pharmacotherapy for Weight Loss
Protecting the Vulnerable: Improving Safety of Antimicrobials in the Elderly Population:
1. Evaluate methods to improve safety of antimicrobial prescribing in the elderly.
2. Review antimicrobial therapy recommendations within Beers Criteria.
3. Examine best antimicrobials practices through case application.
Mastering Migraine Management: Update on Current Therapies:
4. Review current older management strategies for migraine headaches.
5. Discuss role of newer agents including CGRP inhibitors.
6. Examine best practices through case application.
Obesity and Weight Loss:
7. Review risk factors and criteria within obesity
8. Describe appropriate patient populations for weight loss pharmacotherapy.
9. Delineate key characteristics of various approved and future pharmacotherapy options including GLP-1 and GIP agonists.
10. Apply knowledge within patient cases to select an appropriate pharmacotherapy option.
Speakers
Dr. Vondracek has been a faculty member at the University of Colorado Skaggs School of Pharmacy for over 25 years. During this time, her primary focus has been teaching, service to the School and, until recently, practicing as a clinical pharmacist with the University of Colorado Hospital’s inpatient Internal Medicine service. Dr. Vondracek’s scholarly interests include pharmacotherapy challenges in inpatient internal medicine including chronic liver disease, chronic kidney disease, and COPD.
Palliative Care Strategies, Everett, Washington, Certified Pain Educator, Board Certified Oncology Pharmacist, Pain Management / Palliative Care Pharmacist Specialist, Hospice Consultant, Chronic non-cancer Pain Team, LTC Elderly Pain Consultant, Private Pain Management Consultant . Dr. Holmquist has NOfinancial arrangements with any corporate organization that might have an interest in the subject being presented.
Christopher M. Bland, Pharm.D., FCCP, FIDSA, BCPS
Clinical Professor, Clinical and Administrative Pharmacy,
Christopher M. Bland, Pharm.D., FCCP, FIDSA, BCPS Clinical Professor, Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Clinical Pharma- cy Specialist, St. Joseph’s/ Candler Health System, Sa- vannah, Georgia. Co-founder of SERGE-45, practice-based research network, co-founder of TeachMePharm, drug therapy teaching platform.
CE Information
This activity offers 15.0 CME credits (15.0 pharmacology) to attendees.
Accredited by ACPE.
TARGET AUDIENCE/ ACCREDITATION
PHARMACISTS: University Learning Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. These programs are accredited for pharmacists.
NURSE PRACTITIONERS/ NURSES: This course provides 15 contact hours (1.5 CEU) over three days, 5 hours per day, to fulfill the pharmacotherapeutics/ pharmacology requirements for American Nurses Credentialing Center (ANCC) Category 1 Continuing Education Hours for certification renewal. The same hours submitted to renew certification may be submitted to a State Board of Nursing for re-licensure. American Nurses Credentialing Center (ANCC) accepts formally approved continuing education sponsored by organizations accredited or approved by the Accreditation Council for Pharmacy Education (ACPE). .
PHYSICIANS: The AAFP has reviewed Current Treatment Strategies 2024 and deemed it acceptable for up to 15.00 Live AAFP Prescribed credit(s). Term of Approval is from 12/11/2024 to 12/13/2027. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1. CME programs approved by the AAFP are eligible for Category 2 credit (or Category 1-A under special circumstances) through the American Osteopathic Association (AOA).
PHYSICIAN ASSISTANTS: American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for Prescribed credit from AAFP. Physician assistants may report the number of hours stated above of Category I credit for completing this program.
CONSULTANT PHARMACISTS: Some consultant pharmacist boards accept University Learning Systems courses for recertification either as is or with board approval. Please contact your board regarding course approval and ULS with any questions.
CANADIAN PHARMACISTS: Canadian Council on Continuing Education in Pharmacy (CCCEP) accepts courses accredited by the Accreditation Council for Pharmacy Education (ACPE). This credit is applicable to health professionals who may require pharmacology credit.
CANADIAN PHYSICIANS: Members of the College of Family Physicians of Canada are eligible to receive up to 15 MAINPRO-M1 credits for participation in this activity due to reciprocal agreement with the American Academy of Family Physicians.
OTHER HEALTH PROFESSIONALS: Contact your respective board regarding approval.
| Session |
Contact Hours |
ACPE UAN |
Activity |
|
Session 1 |
5 |
0741-0000-24-031-L01-P |
Application |
| Session 2 | 5 | 0741-0000-24-032-L01-P | Application |
| Session 3 | 5 | 0741-0000-24-033-L01-P | Application |
Disclosures
- Dr. Sheryl (Follin) Vondracek, Pharm.D., FCCP, BCPS has no disclosures.
- Dr. Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS, BCACP has no disclosures.
- Dr. Gregory L. Holmquist, PharmD, CPE has no disclosures.
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.
Log in and start activity